Showing 20 of 136 recruiting trials for “plasmablastic-lymphoma”
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
👨⚕️ Michel Zwaan, Prof, Princess Maxima Center for Pediatric Oncology in The Netherlands📍 2 sites📅 Started Aug 2022View details ↗
RecruitingNCT05334069 ↗
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingNCT05750706 ↗
Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative
👨⚕️ Marianna Criscuolo, Fondazione Policlinico Universitario A. Gemelli, IRCCS📍 1 site📅 Started Jun 2022View details ↗
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecruitingNCT05840575 ↗
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
Bright Ideas - CIN Feasibility Study
Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma
👨⚕️ Daobin Zhou, Department of Hematology, Peking University First Hospital📍 1 site📅 Started Oct 2021View details ↗
RecruitingNCT05014165 ↗
Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
👨⚕️ Adam de Smith, PhD, University of Southern California Keck School of Medicine📍 1 site📅 Started Aug 2021View details ↗
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
👨⚕️ Jianxiang Wang, Dr., Institute of Hematology & Blood Diseases Hospital, China📍 11 sites📅 Started Dec 2020View details ↗
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
RecruitingNCT04290000 ↗
Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →